scholarly journals Clinical effect of long-term administration of tolvaptan in patients with heart failure and chronic kidney disease

2018 ◽  
Vol 12 (3) ◽  
pp. 154-160
Author(s):  
Yohei Ono ◽  
Hiroto Takamatsu ◽  
Masahiro Inoue ◽  
Yukio Mabuchi ◽  
Tetsuya Ueda ◽  
...  
2017 ◽  
Vol 81 (11) ◽  
pp. 1736-1738 ◽  
Author(s):  
Yusuke Uemura ◽  
Rei Shibata ◽  
Kenji Takemoto ◽  
Tomohiro Uchikawa ◽  
Masayoshi Koyasu ◽  
...  

Nephrology ◽  
2016 ◽  
Vol 21 (6) ◽  
pp. 490-498 ◽  
Author(s):  
Carsten G. Jungbauer ◽  
Ekrem Uecer ◽  
Stefan Stadler ◽  
Christoph Birner ◽  
Stefan Buchner ◽  
...  

2020 ◽  
Vol 6 (1) ◽  
pp. 55-60
Author(s):  
Khabib Barnoev ◽  
◽  
Sherali Toshpulatov ◽  
Nozima Babajanova ◽  

The article presents the results of a study to evaluate the effectiveness of antiaggregant therapy on the functional status of the kidneys in 115 patients with stage II and III chronic kidney disease on the basis of a comparative study of dipyridamole and allthrombosepin. Studies have shown that long-term administration of allthrombosepin to patients has led to improved renal function.


2020 ◽  
Vol 6 (1) ◽  
pp. 49-54
Author(s):  
Khabib Barnoev ◽  

The article presents the results of a study to assess the functional reserve of the kidneys against the background of a comparative study of antiaggregant therapy dipyridamole and allthrombosepin in 50 patients with a relatively early stage of chronic kidney disease. Studies have shown that long-term administration of allthrombosepin to patients has resulted in better maintenance of kidney functional reserves. Therefore, our research has once again confirmed that diphtheridamol, which is widely used as an antiaggregant drug in chronic kidney disease, does not lag behind the domestic raw material allthrombosepin


Author(s):  
Aaron M. Hein ◽  
Julia J. Scialla ◽  
Jie-Lena Sun ◽  
Stephen J. Greene ◽  
Linda K. Shaw ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document